Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Clinically significant drug interactions with atypical antipsychotics
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinically significant drug interactions with atypical antipsychotics'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Drug Interactions
100%
Clinically Significant
100%
Atypical Antipsychotics
100%
Second-generation Antipsychotics
90%
Antiepileptic Drugs
27%
Adverse Events
18%
Drug Absorption
18%
Plasma Parameters
9%
Antidepressants
9%
Treatment Efficacy
9%
Plasma Concentration
9%
Pharmacodynamic Interactions
9%
Pharmacokinetics-pharmacodynamics (PK-PD)
9%
Cytochrome P450 1A2 (CYP1A2)
9%
Clinical Efficacy
9%
Inducer
9%
Pharmacokinetic Profile
9%
Drug Discovery
9%
Therapeutic Drug Monitoring
9%
Cytochrome P450 Enzymes
9%
Protease Inhibitors
9%
Psychiatric Patients
9%
Carbamazepine
9%
Cytochrome P450 (CYP450)
9%
Patients with Schizophrenia
9%
Pharmacokinetic Drug Interactions
9%
Pharmacodynamic Mechanism
9%
Bipolar Disorder
9%
Drug Transporters
9%
Therapeutic Treatment
9%
Plasma Drug Concentration
9%
Therapeutic Plasma
9%
Drug Monitoring
9%
Clinical Case Reports
9%
Lurasidone
9%
Preclinical Development
9%
Co-administered Drugs
9%
Phenobarbital
9%
Valproate
9%
Site Activity
9%
Ziprasidone
9%
Anti-infective Agents
9%
Dose Dependence
9%
Receptor Sites
9%
Time Dependence
9%
Treatment Interventions
9%
Competitive Effect
9%
Pharmaceutical Interactions
9%
Pharmaceutical Mechanism
9%
Phase II Metabolism
9%
Fluoroquinolones
9%
Phenytoin
9%
Additive Effect
9%
Mood Stabilizers
9%
Psychotic
9%
Clinical Reports
9%
Pharmacology, Toxicology and Pharmaceutical Science
Atypical Antipsychotics
100%
Drug Interaction
100%
Pharmacodynamics
30%
Pharmacokinetics
30%
Adverse Event
20%
Anticonvulsive Agent
20%
Drug Absorption
20%
Drug-Drug Interaction
10%
Selective Serotonin Reuptake Inhibitor
10%
Receptor
10%
CYP1A2
10%
Clinical Study
10%
Bioavailability
10%
Antiinfective Agent
10%
Therapeutic Drug Monitoring
10%
Drug Discovery
10%
Drug Concentration
10%
Combination Therapy
10%
Proteinase Inhibitor
10%
Carbamazepine
10%
Cytochrome P450
10%
Bipolar Disorder
10%
Phenobarbital
10%
Cytochrome P450 Inhibitor
10%
Lurasidone
10%
Sodium Valproate
10%
Quinolone Derivative
10%
Mood Stabilizer
10%
Antidepressant
10%
Phenytoin
10%
Ziprasidone
10%
Cytochrome P450 Inducer
10%